News
Archive
Resolve Therapeutics publishes results of RSLV-132 Phase 2 long COVID study
Finally, Graphene electronic devices available for all
Ventyx Biosciences reports clinical data for its NLRP3 inhibitor portfolio and provides pipeline updates at virtual investor event
NorthSea Therapeutics initiates Phase 2A trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)
Resolve Therapeutics announces publication of Lupus clinical trial results
biomodal delivers the 6-base genome with a powerful new multiomic solution, duet evoC
Back To NewsMay 12, 2023